<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Challenges and approaches to establishing multi-pathogen serosurveillance: Findings from the 2023 Serosurveillance Summit</title>
				<funder>
					<orgName type="full">Johns Hopkins Bloomberg School of Public Health</orgName>
				</funder>
				<funder>
					<orgName type="full">Bill and Melinda Gates Foundation</orgName>
				</funder>
				<funder>
					<orgName type="full">University of Colorado</orgName>
				</funder>
				<funder>
					<orgName type="full">Elimination, Pan American Health Organization</orgName>
				</funder>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Andrea</forename><forename type="middle">C</forename><surname>Carcelen</surname></persName>
							<email>acarcel1@jhmi.edu</email>
						</author>
						<author>
							<persName><forename type="first">Alex</forename><forename type="middle">C</forename><surname>Kong</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of International Health</orgName>
								<orgName type="institution">Johns Hopkins Bloomberg School of Public Health</orgName>
								<address>
									<settlement>Baltimore</settlement>
									<region>MD</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Saki</forename><surname>Takahashi</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Department of Epidemiology</orgName>
								<orgName type="institution">Johns Hopkins Bloomberg School of Public Health</orgName>
								<address>
									<settlement>Baltimore</settlement>
									<region>MD</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Sonia</forename><surname>Hegde</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Department of Epidemiology</orgName>
								<orgName type="institution">Johns Hopkins Bloomberg School of Public Health</orgName>
								<address>
									<settlement>Baltimore</settlement>
									<region>MD</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Thomas</forename><surname>Jaenisch</surname></persName>
							<affiliation key="aff2">
								<orgName type="institution">University of Colorado</orgName>
								<address>
									<settlement>Boulder</settlement>
									<region>CO</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">May</forename><surname>Chu</surname></persName>
							<affiliation key="aff2">
								<orgName type="institution">University of Colorado</orgName>
								<address>
									<settlement>Boulder</settlement>
									<region>CO</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Rosemary</forename><surname>Rochford</surname></persName>
							<affiliation key="aff2">
								<orgName type="institution">University of Colorado</orgName>
								<address>
									<settlement>Boulder</settlement>
									<region>CO</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Natalya</forename><surname>Kostandova</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Department of Epidemiology</orgName>
								<orgName type="institution">Johns Hopkins Bloomberg School of Public Health</orgName>
								<address>
									<settlement>Baltimore</settlement>
									<region>MD</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Emily</forename><forename type="middle">S</forename><surname>Gurley</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Department of Epidemiology</orgName>
								<orgName type="institution">Johns Hopkins Bloomberg School of Public Health</orgName>
								<address>
									<settlement>Baltimore</settlement>
									<region>MD</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Amy</forename><surname>Wesolowski</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Department of Epidemiology</orgName>
								<orgName type="institution">Johns Hopkins Bloomberg School of Public Health</orgName>
								<address>
									<settlement>Baltimore</settlement>
									<region>MD</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Andrew</forename><forename type="middle">S</forename><surname>Azman</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Department of Epidemiology</orgName>
								<orgName type="institution">Johns Hopkins Bloomberg School of Public Health</orgName>
								<address>
									<settlement>Baltimore</settlement>
									<region>MD</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="institution">Geneva University Hospitals</orgName>
								<address>
									<settlement>Geneva</settlement>
									<country key="CH">Switzerland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Fiona</forename><forename type="middle">R M</forename><surname>Van Der Klis</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Center for Infectious Disease Control National Institute for Public Health and the Environment (RIVM) Bilthoven</orgName>
								<address>
									<country key="NL">The Netherlands</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">;</forename><surname>Gerco Den Hartog</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Center for Infectious Disease Control National Institute for Public Health and the Environment (RIVM) Bilthoven</orgName>
								<address>
									<country key="NL">The Netherlands</country>
								</address>
							</affiliation>
							<affiliation key="aff5">
								<orgName type="laboratory">Laboratory of Medical Immunology</orgName>
								<orgName type="institution">Radboud UMC</orgName>
								<address>
									<settlement>Nijmegen</settlement>
									<country key="NL">The Netherlands</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Christopher</forename><surname>Drakeley</surname></persName>
							<affiliation key="aff6">
								<orgName type="department">London School of Tropical Medicine and Health</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Christopher</forename><surname>Heaney</surname></persName>
							<affiliation key="aff7">
								<orgName type="department">Environmental Health and Engineering Department</orgName>
								<orgName type="institution">Johns Hopkins Bloomberg School of Public Health</orgName>
								<address>
									<settlement>Baltimore</settlement>
									<region>MD</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Amy</forename><forename type="middle">K</forename><surname>Winter</surname></persName>
							<affiliation key="aff8">
								<orgName type="institution">University of Georgia</orgName>
								<address>
									<settlement>Athens</settlement>
									<region>GA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Henrik</forename><surname>Salje</surname></persName>
							<affiliation key="aff9">
								<orgName type="department">Department of Genetics</orgName>
								<orgName type="institution">University of Cambridge</orgName>
								<address>
									<settlement>Cambridge</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Isabel</forename><surname>Rodriguez-Barraquer</surname></persName>
							<affiliation key="aff10">
								<orgName type="department">Department of Medicine</orgName>
								<orgName type="institution">University of California</orgName>
								<address>
									<settlement>San Francisco</settlement>
									<region>CA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Daniel</forename><forename type="middle">T</forename><surname>Leung</surname></persName>
							<email>daniel.leung@utah.edu</email>
							<affiliation key="aff11">
								<orgName type="department">Division of Infectious Diseases</orgName>
								<orgName type="institution">University of Utah School of Medicine</orgName>
								<address>
									<settlement>Salt Lake City</settlement>
									<region>UT</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Sammy</forename><forename type="middle">M</forename><surname>Njenga</surname></persName>
							<email>snjenga@kemri.go.ke</email>
							<affiliation key="aff12">
								<orgName type="institution">Kenya Medical Research Institute (KEMRI)</orgName>
								<address>
									<settlement>Nairobi</settlement>
									<country key="KE">Kenya</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Wangeci</forename><surname>Kagucia</surname></persName>
							<email>ekagucia@kemri-wellcome.org</email>
							<affiliation key="aff13">
								<orgName type="institution">KEMRI-Wellcome Trust Research Programme</orgName>
								<address>
									<settlement>Kilifi</settlement>
									<country key="KE">Kenya</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">;</forename><surname>Kondwani</surname></persName>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">C</forename><surname>Jambo</surname></persName>
							<email>kjambo@mlw.mw</email>
							<affiliation key="aff14">
								<orgName type="institution">Malawi-Liverpool-Wellcome Programme (MLW)</orgName>
								<address>
									<settlement>Blantyre</settlement>
									<country key="MW">Malawi</country>
								</address>
							</affiliation>
							<affiliation key="aff15">
								<orgName type="institution">Liverpool School of Tropical Medicine</orgName>
								<address>
									<settlement>Liverpool</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Nicole</forename><surname>Wolter</surname></persName>
							<email>nicolew@nicd.ac.za</email>
							<affiliation key="aff16">
								<orgName type="department">Centre for Respiratory Diseases and Meningitis</orgName>
								<orgName type="institution">National Institute for Communicable Diseases of the National Health Laboratory Service</orgName>
								<address>
									<settlement>Johannesburg</settlement>
									<country key="ZA">South Africa</country>
								</address>
							</affiliation>
							<affiliation key="aff17">
								<orgName type="department" key="dep1">School of Pathology</orgName>
								<orgName type="department" key="dep2">Faculty of Health Sciences</orgName>
								<orgName type="institution">University of the Witwatersrand</orgName>
								<address>
									<settlement>Johannesburg</settlement>
									<country key="ZA">South Africa</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Richelle</forename><forename type="middle">C</forename><surname>Charles</surname></persName>
							<email>rcharles@mgh.harvard.edu</email>
							<affiliation key="aff18">
								<orgName type="department">Harvard T.H. Chan School of Public Health</orgName>
								<orgName type="institution" key="instit1">Massachusetts General Hospital</orgName>
								<orgName type="institution" key="instit2">Harvard Medical School</orgName>
								<address>
									<settlement>Boston</settlement>
									<region>MA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Martha-Idalí</forename><surname>Saboyá-Díaz</surname></persName>
						</author>
						<author>
							<persName><surname>Drph</surname></persName>
							<affiliation key="aff19">
								<orgName type="department">Department of Communicable Diseases Prevention, Control, and Elimination</orgName>
								<orgName type="institution">American Health Organization</orgName>
								<address>
									<addrLine>Washington DC</addrLine>
									<country>Pan, USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Diana</forename><forename type="middle">L</forename><surname>Martin</surname></persName>
							<affiliation key="aff20">
								<orgName type="department" key="dep1">Division of Parasitic Diseases and Malaria</orgName>
								<orgName type="department" key="dep2">Centers for Disease Control and Prevention</orgName>
								<address>
									<settlement>Atlanta</settlement>
									<region>GA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">William</forename><forename type="middle">J</forename><surname>Moss</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of International Health</orgName>
								<orgName type="institution">Johns Hopkins Bloomberg School of Public Health</orgName>
								<address>
									<settlement>Baltimore</settlement>
									<region>MD</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Department of Epidemiology</orgName>
								<orgName type="institution">Johns Hopkins Bloomberg School of Public Health</orgName>
								<address>
									<settlement>Baltimore</settlement>
									<region>MD</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><surname>Rodriguez - Barraquer</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of International Health</orgName>
								<orgName type="institution">Johns Hopkins Bloomberg School of Public Health</orgName>
								<address>
									<settlement>Baltimore</settlement>
									<region>MD</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Kenya</forename><surname>Medical</surname></persName>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Kondwani</forename><forename type="middle">C</forename><surname>Jambo</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Malawi-Liverpool- Wellcome</forename><surname>Programme</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Martha</forename><surname>- Idalí</surname></persName>
						</author>
						<author>
							<affiliation key="aff21">
								<address>
									<addrLine>415 N Washington St, Floor 5</addrLine>
									<postCode>21224</postCode>
									<settlement>Baltimore</settlement>
									<region>MD</region>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff22">
								<orgName type="institution" key="instit1">Medicine</orgName>
								<orgName type="institution" key="instit2">University of California</orgName>
								<address>
									<settlement>San Francisco</settlement>
									<region>CA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff23">
								<orgName type="department" key="dep1">MD Division of Infectious Diseases</orgName>
								<orgName type="department" key="dep2">School of Medicine</orgName>
								<orgName type="institution">University of Utah</orgName>
								<address>
									<settlement>Salt Lake City</settlement>
									<region>UT</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff24">
								<orgName type="institution">Research Institute (KEMRI)</orgName>
								<address>
									<settlement>Nairobi</settlement>
									<country key="KE">Kenya</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff25">
								<orgName type="department">PhD KEMRI-Wellcome Trust Research Programme</orgName>
								<address>
									<settlement>Kilifi</settlement>
									<country key="KE">Kenya</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff26">
								<orgName type="department" key="dep1">MLW</orgName>
								<orgName type="department" key="dep2">School of Tropical Medicine</orgName>
								<address>
									<settlement>Blantyre, Liverpool</settlement>
									<country>Malawi; Liverpool, UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff27">
								<orgName type="department">PhD Centre for Respiratory Diseases and Meningitis</orgName>
								<orgName type="laboratory">National Institute for Communicable Diseases of the National Health Laboratory Service</orgName>
								<address>
									<settlement>Johannesburg</settlement>
									<country key="ZA">South Africa</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff28">
								<orgName type="department">School of Pathology</orgName>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff29">
								<orgName type="department">Faculty of Health Sciences</orgName>
								<orgName type="institution">University of the Witwatersrand</orgName>
								<address>
									<settlement>Johannesburg</settlement>
									<country key="ZA">South Africa</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff30">
								<orgName type="department" key="dep1">Harvard Medical School</orgName>
								<orgName type="department" key="dep2">School of Public Health</orgName>
								<orgName type="institution">MD Massachusetts General Hospital</orgName>
								<address>
									<addrLine>Harvard T.H. Chan</addrLine>
									<settlement>Boston</settlement>
									<region>MA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff31">
								<orgName type="department">DrPH Department of Communicable</orgName>
							</affiliation>
						</author>
						<title level="a" type="main">Challenges and approaches to establishing multi-pathogen serosurveillance: Findings from the 2023 Serosurveillance Summit</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">90B38CB17994BCBF61FCD054F3254828</idno>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.8.0" ident="GROBID" when="2025-10-22T06:23+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>serological surveillance</term>
					<term>multiplex bead immunoassay</term>
					<term>integrated surveillance</term>
					<term>infectious diseases</term>
					<term>serology</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p>Multiplex-based serological surveillance is a valuable but underutilized tool to understand gaps in population-level exposure, susceptibility, and immunity to infectious diseases. Assays for which blood samples can be tested for antibodies against several pathogens simultaneously, such as multiplex bead immunoassays, can more efficiently integrate public health surveillance in low-and middle-income countries. From March 7-8, 2023, a group of experts representing research institutions, multilateral organizations, private industry, and country partners met to discuss experiences, identify challenges and solutions, and create a community of practice for integrated, multi-pathogen serosurveillance using multiplex bead assay technologies. Participants were divided into six working groups: (1) supply chain; (2) laboratory assays; (3) seroepidemiology; (4) data analytics; (5) sustainable implementation; and (6) use case scenarios. These working groups discussed experiences, challenges, solutions, and research needs to facilitate integrated, multi-pathogen serosurveillance for public health. Several solutions were proposed to address challenges that cut across working groups.</p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p>The World Health Organization (WHO) recently introduced collaborative surveillance as one of five interconnected components of health emergency preparedness, response, and resilience. <ref type="bibr" target="#b0">1,</ref><ref type="bibr" target="#b1">2</ref> A core objective of collaborative surveillance is to break down siloed disease surveillance systems and replace them with a collaborative and integrated system across diseases, public and private sectors, and administrative levels.</p><p>Serological surveillance, or serosurveillance, complements traditional public health surveillance for infectious diseases through the collection and analysis of specimens (e.g., serum, blood, or oral fluid) to measure antibodies to pathogens and estimate population-level exposure, susceptibility, and immunity to infectious diseases. <ref type="bibr" target="#b2">3</ref> This information can guide public health policies and programs for the control and elimination of several communicable diseases, including vaccinepreventable diseases (VPDs), neglected tropical diseases (NTDs), and emerging infectious diseases (EIDs), among others. While serosurveillance has been used for decades, the COVID-19 pandemic amplified interest in serology. <ref type="bibr" target="#b3">4</ref> The development of technologies like multiplex bead immunoassays (MBIAs), which allow for the simultaneous detection of antibodies to more than one pathogen in a single assay, rapidly advanced the ability to efficiently conduct integrated, multipathogen serosurveillance. <ref type="bibr" target="#b2">3,</ref><ref type="bibr" target="#b4">5</ref> These technologies enable health systems to monitor exposure, susceptibility, and immunity to multiple pathogens with limited additional resources compared to using single-pathogen assays. <ref type="bibr" target="#b5">6</ref> MBIAs have been developed for detecting antibodies against a range of pathogens including VPDs <ref type="bibr" target="#b6">[7]</ref><ref type="bibr" target="#b7">[8]</ref><ref type="bibr" target="#b8">[9]</ref> respiratory pathogens; <ref type="bibr" target="#b9">10</ref> NTDs; <ref type="bibr" target="#b10">[11]</ref><ref type="bibr" target="#b11">[12]</ref><ref type="bibr" target="#b12">[13]</ref><ref type="bibr" target="#b13">[14]</ref><ref type="bibr" target="#b14">[15]</ref> malaria; <ref type="bibr" target="#b15">16,</ref><ref type="bibr" target="#b16">17</ref> sexually transmitted infections; <ref type="bibr" target="#b17">18</ref> EIDs; <ref type="bibr" target="#b18">19</ref> arboviruses; <ref type="bibr" target="#b19">20</ref> and SARS-CoV-2. <ref type="bibr" target="#b20">21</ref> Integrating serosurveillance across multiple pathogens could efficiently leverage financial resources and personnel as well as metadata obtained from questionnaires.</p><p>Integration with other surveillance programs (e.g., diagnostic, syndromic, and wastewater surveillance) <ref type="bibr" target="#b2">3</ref> could further improve the efficiency of surveillance systems to control the spread of disease.</p><p>Despite the MBIA being a powerful tool for public health surveillance, several barriers have prevented the widespread adoption of these technologies, particularly in low-and middle-income countries (LMICs), where they might be especially useful. <ref type="bibr" target="#b21">22</ref> Through partnerships with academic and government research institutions, multi-pathogen serosurveillance has been conducted in sub-Saharan Africa, <ref type="bibr" target="#b22">23,</ref><ref type="bibr" target="#b23">24</ref> Asia, <ref type="bibr" target="#b2">3,</ref><ref type="bibr" target="#b24">25,</ref><ref type="bibr" target="#b25">26</ref> and the Americas. <ref type="bibr" target="#b21">22,</ref><ref type="bibr" target="#b26">27,</ref><ref type="bibr" target="#b27">28</ref> CDC and the Pan American Health Organization developed guidance for program managers to design and conduct integrated multi-pathogen serosurveillance. <ref type="bibr" target="#b27">28</ref> To discuss the opportunities and complexities with establishing integrated, multipathogen serosurveillance, experts from the Collaboration on Integrated Biomarkers Surveillance (CIBS) met in 2018 to catalog pathogens for inclusion in multiplex serological assays, lay out objectives for an integrated platform, identify potential use cases, and discuss advocacy. <ref type="bibr" target="#b28">29</ref>  </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Serosurveillance Summit Meeting</head><p>Experts across a range of institutions and fields participated, including researchers, multilateral organizations, country partners, private sector companies, and supply chain organizations. Participants were divided into two of six working groups: (1)   supply chain, (2) laboratory assays, (3) seroepidemiology, (4) data analytics, (5)   sustainable implementation, and (6) use case scenarios. The objectives of the workshop were to share experiences establishing integrated, multi-pathogen serosurveillance with a focus on MBIAs; identify key challenges, potential solutions, and research needs for integrated serosurveillance using MBIAs; and establish a community of practice of technical experts.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Figure 1:</head><p>A framework depicting key steps for establishing a sustainable integrated serosurveillance system. The steps correspond with the six working groups, except for using data for program action which is part of the sustainable implementation working group.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Experiences and challenges</head><p>Participants shared their experiences with multi-pathogen serosurveillance (Annex 1). Based on these discussions, key issues that countries using multiplex serosurveillance encounter were outlined.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Public health questions and use cases</head><p>Because multi-pathogen surveillance involves multiple programs and partners, it can be challenging to generate buy-in from all stakeholders and identify potential programmatic impact early in the planning process. As more pathogens are included, additional groups working on different diseases will need to be engaged.</p><p>Programmatic or research questions were framed as "use cases" for which serosurveillance is most likely to add value to existing surveillance systems. Table <ref type="table" target="#tab_0">1</ref> presents five of the most common use cases identified and linked target pathogen(s) of interest. Several groups of pathogens were considered most relevant, including VPDs, emerging pathogens, NTDs, and other pathogens associated with high disease burden. A key issue is identifying the appropriate target population for the question of interest. Because pathogens affect individuals across different demographic characteristics (e.g., age), selecting a target population to cover all pathogens of interest is challenging. Other challenges include defining population sampling strategies and sample sizes to answer multiple questions simultaneously and determining the optimal survey frequency to measure temporal trends across pathogens and address programmatic needs. One viable option includes nesting specimen collection within existing surveys that sample large populations across multiple characteristics (e.g., Demographic and Health Surveys, Multiple Indicator Cluster Surveys). Less resource-intensive sampling strategies like using residual blood specimens (e.g., from health facility laboratories or routine screening of pregnant women) can reduce costs while still capturing a range of populations and time points. Additionally, specimen type (e.g. dried blood spots, venous blood and oral fluid) must balance feasibility of collection and assay validity across all pathogens.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Supplies</head><p>One of the biggest challenges raised by multiple groups was related to the supply chain for assay reagents and equipment. Challenges included procuring, maintaining, and repairing platform technology, such as Luminex instruments.</p><p>Procuring quality-assured beads and assay reagents in a space with few smallscale producers of conjugated beads is also an issue. Other challenges with supply chain sustainability involve understanding and addressing country-specific limitations to importation, maintaining the cold chain, and establishing procurement procedures and processes for reagents and supplies.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Laboratory assays</head><p>For multi-pathogen serosurveillance, several issues related to assay development, antigen discovery and validation, identification of proper controls, and assay performance must be addressed. Many research groups have developed standard operating procedures (SOPs) for equipment maintenance, assay techniques, assay development, quality control, and other key multiplex serology operations.</p><p>However, resources such as positive and negative controls are not always available and require continuous support to laboratories for appropriate use. Furthermore, quality controls to validate assay runs and track assay performance over time are needed. Standardization holds the promise to make serosurveillance results more comparable between laboratories, but this is currently hampered by the limited availability of reference standards. Available reference reagents are typically calibrated for a specific pathogen, not for a broad range of them. Consequently, to report international units, standards need to be calibrated against each other or an in-house standard must be built and calibrated against multiple standards.</p><p>Developing assays requires knowledge of the immunogenicity of antigens, kinetics of antibody responses, and relevance for assessing disease burden or protective immunity (i.e., correlates of immune protection). Because assay development can be technically challenging and requires thorough validation, the number of laboratories that currently undertake assay development is limited. High demand and inadequate capacity limit the availability of antigen-coupled beads, which are currently produced by a small number of research groups, although technology transfer initiatives are ongoing. For countries considering implementing multiplex serosurveillance but unable to develop assays, commercial options are also limited.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Data analysis and interpretation</head><p>There are currently no standardized approaches to cleaning raw laboratory data and establishing seropositivity thresholds, as this varies by antigen, the availability of controls, and population. This first stage of analysis includes performing quality control checks, evaluating serial dilution standard curves, and ensuring steps to normalize data are appropriately applied. Translating cleaned data into useful epidemiologic inference requires analytical approaches that model the normalized quantitative values or the establishment of reasonable cut-points for seropositivity that are relevant for the specific use case. Additionally, the interpretation of pathogen-specific age patterns and geographic distributions of seroprevalence requires supplementing laboratory data with demographic characteristics and contextualized epidemiologic understanding of the specific pathogens. The use of serological data for computing age seroprevalence curves and estimating epidemiological parameters, such as forces of infection, is established for wellcharacterized antigens. A key remaining challenge is selecting and implementing appropriate analytical approaches (and metadata) to answer questions of interest for less-well-characterized antigens as well as across multiple antigens or pathogens simultaneously. Further, there is a need for data analytic pipelines to facilitate the interpretation of data by balancing detail and complexity and producing user-friendly data visualizations such as spatial maps.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Data for program action</head><p>Given the complexities of analyzing multiple pathogens simultaneously, it can be challenging to generate interpretable and easily visualized results for target audiences such as policy makers and program managers. The time from serosurvey data collection to dissemination of results is often long (months), which makes it challenging to use results for decision making. Serosurvey data should be triangulated with other data sources for interpretation of the epidemiological findings for each disease. When serosurveillance for several pathogens are simultaneously analyzed and presented, it can be challenging to contextualize all findings in a succinct, clear manner.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Cross-cutting challenges</head><p>Training needs included supply chain logistics and procurement so laboratories can place their supply orders and anticipate shortages. Similarly, training on instrument use and routine maintenance are needed to sustain high instrument performance and minimize downtime and costly repairs. There were also challenges with technology transfer, including training on the MBIA, bead coupling and validation, and quality control procedures. Additionally, there is a strong need for training in data analytics, as multi-pathogen serosurveillance data are complex and most useful when combined with complementary data such as vaccination coverage or case-based disease surveillance data.  </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Establishing a laboratory network and building partnerships</head><p>A laboratory support network would facilitate knowledge sharing and troubleshooting at country, regional, and global levels, helping to connect laboratory groups. Partnering with private companies would support commercialization of panels and sharing of know-how regarding supply chain constraints. Partnering with supply chain experts would enable procurement and packaging of common reagents and materials to streamline ordering processes and avoid delays caused by stockouts. Regional networks could also allow groups to share limited resources-including access to instruments and materials like antigen-coupled beads-and to pool demand for these resources. Regional hubs could be characterized by function (e.g., coupling antigens to beads and providing quality control) to help meet the needs of different groups, further building a collaborative network.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Generating political buy-in for multiplex serosurveillance</head><p>Participants viewed the establishment of buy-in from governments, funders, and regulatory agencies as essential for the introduction and scale-up of multipathogen serosurveillance. Approaches to achieving support and fostering greater participation from these entities include exploring standardized approval processes for the importation of products necessary for multi-pathogen serosurveillance, developing a taxonomy of pathogen-specific antigens paired to scientific and policy-relevant use cases, involving governmental agencies in training initiatives, and developing analytical and visualization pipelines to aid understanding.</p><p>Garnering high level regional and international support to develop guidance and recommendations for the implementation and use of integrated serosurveillance was considered a priority. Organizations like PAHO and the US CDC have developed documents that were discussed as starting points. <ref type="bibr" target="#b27">28</ref> This goal could be supported through conversations with decision makers to demonstrate how integrated, multipathogen serosurveillance can complement existing disease surveillance systems and by providing successful case studies. Generating community buy-in through communication of the benefits and limitations of serosurveillance is also critical as exploring the value of integrated serosurveillance hinges on their participation.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p>Serosurveillance provides valuable information to guide public health programs, especially when triangulated with data from other surveillance systems. In isolation, serosurveillance systems are costly to establish and sustain. <ref type="bibr" target="#b27">28,</ref><ref type="bibr" target="#b35">36</ref> Serosurveillance data is underutilized due to the heterogeneity of assays and the delay in disseminating results to health authorities for meaningful program impact. <ref type="bibr" target="#b36">37,</ref><ref type="bibr" target="#b37">38</ref> Ideally, integration of serosurveillance with routine public health activities can reduce costs and make it more sustainable but requires sufficient buy-in and funding. <ref type="bibr" target="#b5">6,</ref><ref type="bibr" target="#b13">14,</ref><ref type="bibr" target="#b22">23,</ref><ref type="bibr" target="#b38">39</ref> The lessons learned from experiences establishing serosurveillance across multiple countries should be shared to promote further investment in this technology.</p><p>For serosurveillance to have programmatic impact, data must be available in a timely fashion. Several bottlenecks cause delays: planning epidemiologically relevant serosurveys; procuring materials and equipment; and cleaning, analyzing, and interpreting data. <ref type="bibr" target="#b28">29</ref> Some approaches, such as developing standard operating procedures, addressing supply chain issues, optimizing data analysis pipelines, training local health researchers, and sharing preliminary results with decision makers can shorten the time for data to be used for action. <ref type="bibr" target="#b21">22</ref> Timely serosurveillance data provides insights into disease transmission patterns and population vulnerability to outbreaks to guide control and elimination strategies.</p><p>Financial, technical, and political support are also needed to overcome these bottlenecks. For example, the development of a commercial panel for frequently tested antibodies could address supply chain constraints, but commercialization restricts flexibility to modify the pathogens that can be tested. For commercialization of panels, there will need to be sufficient demand. Without adequate resources, serosurveillance efforts may only be pilots or ad hoc endeavors. Investment in the development of country-led multi-pathogen serosurveillance systems, like PAHO's, <ref type="bibr" target="#b27">28</ref> can expand the number of countries conducting multi-pathogen serosurveillance.</p><p>In addition to the use cases presented, there are additional questions of public health importance that could be explored (e.g., optimizing vaccination schedules).</p><p>Recently, the most common use case was measuring the spread of SARS-CoV-2;</p><p>seroprevalence studies were conducted in 149 countries. <ref type="bibr" target="#b3">4</ref> This allowed tracking the spread of the virus, identifying transmission dynamics, monitoring population immunity, and evaluating vaccine program performance. <ref type="bibr" target="#b39">40,</ref><ref type="bibr" target="#b40">41</ref> Leveraging the capacity building, networking, platforms, and expertise developed during the COVID-19 pandemic, could better prepare us for the next emerging pathogen and support surveillance systems for diseases that are underfunded.</p><p>The global response to the COVID-19 pandemic also demonstrated the power of coordination across institutions. Monitoring seroprevalence and population immunity in different settings harnessed learnings across the globe. Though harmonized approaches were feasible for SARS-CoV-2 and allowed for crosscountry comparisons, many pathogens need additional research to allow for such comparisons. Some vaccine-preventable diseases like measles and rubella already have standardized international controls, agreed upon correlates of protection, existing laboratory networks, and clear programmatic actions that can be informed by serological data. <ref type="bibr" target="#b41">42</ref> As multiplex panels are developed for different pathogens, similar standardization could enable results to be more readily compared across settings. Although VPDs are an area where standardization is within reach, achieving this aim across a diverse array of pathogens-especially considering the unique epidemiological profiles and priorities of different countries-will require more developed serosurveillance systems and international coordination.</p><p>While multi-pathogen serosurveillance has traditionally been used in high-income countries (HICs), <ref type="bibr" target="#b42">43</ref> it has also been used in LMICs, often with a high degree of technical support from organizations based in HICs. Some studies include samples from LMICs that were tested entirely in an HIC, <ref type="bibr" target="#b43">44</ref> in both LMICs and HICs, <ref type="bibr" target="#b20">21,</ref><ref type="bibr" target="#b44">45,</ref><ref type="bibr" target="#b44">45</ref> and entirely in an LMIC. <ref type="bibr" target="#b22">23,</ref><ref type="bibr" target="#b45">[46]</ref><ref type="bibr" target="#b46">[47]</ref><ref type="bibr" target="#b47">[48]</ref><ref type="bibr" target="#b48">[49]</ref>  Building on the momentum from previous efforts, the 2023 Serosurveillance Summit provides further impetus to advance collaboration among countries to conduct multi-pathogen serosurveillance. Participants will continue serving on working groups to put into practice the proposed solutions outlined above. This community of practice brings together a network of scientists and practitioners to facilitate knowledge sharing and develop a platform for multi-pathogen, multicountry serosurveillance. These established networks and relationships could facilitate rapid response efforts for future emerging pathogens. As the world moves to reclaim the progress against infectious diseases that was disrupted by the COVID-19 pandemic-and to enhance preparedness to prevent or mitigate the next pandemic-the appetite for establishing multi-pathogen serosurveillance systems has never been greater.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Declaration of interests</head><p>MISD is a staff member of the Pan American Health Organization. The authors alone are responsible for the views expressed in this publication, and they do not necessarily represent the decisions or policies of the Pan American Health</p><p>Organization.</p><p>NW has received grant funding from the US CDC, the Bill and Melinda Gates Foundation and Sanofi Pasteur.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Disclaimer</head><p>The </p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head></head><label></label><figDesc>Building on this work, in March 2023, the International Vaccine Access Center at the Johns Hopkins Bloomberg School of Public Health, with support from the Bill and Melinda Gates Foundation (BMGF) and collaborators at the Center for Global Health at the University of Colorado Anschutz Medical Campus, convened a serosurveillance summit that further explored topics related to the use of MBIAs for multi-pathogen serosurveillance.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1 . Use Cases for Multiplex Serosurveillance Use Cases and a Representative Example Example Pathogens Estimating the burden and distribution of infections</head><label>1</label><figDesc></figDesc><table><row><cell>to</cell><cell>NTDs Trypanosoma cruzi (Chagas disease), chikungunya virus, Taenia solium (cysticercosis), Strongyloides spp., Treponema pallidum subspecies pertenue (yaws)</cell></row><row><cell>complement or fill gaps in existing surveillance</cell><cell>Enteric pathogens Campylobacter spp., Vibrio cholerae, Cryptosporidium, Giardia</cell></row><row><cell>systems 30</cell><cell>Malaria Plasmodium species</cell></row><row><cell></cell><cell>HIV</cell></row><row><cell></cell><cell>Respiratory viruses</cell></row><row><cell></cell><cell>respiratory syncytial virus (RSV), influenza virus</cell></row><row><cell>Identifying</cell><cell>Filoviruses</cell></row><row><cell>emerging and</cell><cell>Ebolaviruses, Marburg virus</cell></row><row><cell>reemerging infections 31</cell><cell>Other viruses Lassa virus, mpox virus SARS-CoV-2, Zika virus</cell></row><row><cell>Identifying vaccine</cell><cell>Childhood diseases</cell></row><row><cell>program reach or gaps and geographic</cell><cell>measles virus, polioviruses, rubella virus, diphtheria, tetanus, pertussis</cell></row><row><cell>or demographic gaps 32</cell><cell>Other viruses SARS-CoV-2,</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>yellow fever virus Assessing changes in pathogen exposure due to behavioral, environmental, or (non-) pharmaceutical interventions or environmental changes 33</head><label></label><figDesc></figDesc><table><row><cell>settings for diseases with elimination goals 34</cell><cell>(Guinea worm), Leishmania spp. (visceral leishmaniasis), nematodes (lymphatic filariasis), Onchocerca volvulus (onchocerciasis), Treponema pallidum subspecies pertenue (yaws), Trypanosoma brucei (human African trypanosomiasis)</cell></row><row><cell></cell><cell>Vaccine-preventable diseases</cell></row><row><cell></cell><cell>polioviruses</cell></row><row><cell></cell><cell>Malaria Plasmodium spp. (sub-national levels)</cell></row><row><cell>Study design</cell><cell></cell></row><row><cell></cell><cell>NTDs</cell></row><row><cell></cell><cell>chikungunya virus, dengue virus, lymphatic filariasis</cell></row><row><cell></cell><cell>Bacteria Streptococcus pneumoniae spp., Salmonella serotype Typhi (Typhoid)</cell></row><row><cell></cell><cell>Malaria Plasmodium species</cell></row><row><cell>Monitoring peri-and post-elimination</cell><cell>NTDs Chlamydia trachomatis (trachoma), Dracunculus medinensis</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 2</head><label>2</label><figDesc>summarizes challenges identified in each working group. Additional details are available in the full meeting report.<ref type="bibr" target="#b34">35</ref> </figDesc><table /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Table 2 .</head><label>2</label><figDesc>Key challenges identified by the working groups , and train-the-trainer initiatives. These approaches could enable users to perform MBIAs, service and troubleshoot bead-based multiplex platforms, and produce or procure antigen-coupled beads. While discussion of capacity building focused on LMICs, many areas were relevant for users in all countries.</figDesc><table><row><cell>Working</cell><cell>Key Challenges</cell></row><row><cell>Group</cell><cell></cell></row><row><cell>Supply Chain</cell><cell>Procuring and maintaining appropriate platform technology,</cell></row><row><cell></cell><cell>producing and procuring quality-assured beads and assays,</cell></row><row><cell></cell><cell>commercializing kits, maintaining the cold chain, understanding</cell></row><row><cell></cell><cell>and addressing country-specific limitations to importation, and</cell></row><row><cell></cell><cell>limited human and technological capacity to anticipate and</cell></row><row><cell></cell><cell>avoid supply chain issues</cell></row><row><cell>Seroepidemiolog</cell><cell>Selecting sample populations and sample sizes, establishing</cell></row><row><cell>y</cell><cell>the frequency of sampling, identifying and validating less</cell></row><row><cell></cell><cell>resource-intensive sampling strategies, defining sampling</cell></row><row><cell></cell><cell>approaches that answer multiple questions, determining core</cell></row><row><cell></cell><cell>individual-and household-level data to collect, and linking</cell></row><row><cell></cell><cell>serosurvey antigens to study design for programmatic impact</cell></row><row><cell>Laboratory</cell><cell>Supporting technology transfer and training, sharing best</cell></row><row><cell>Assays</cell><cell>practices and protocols, standardizing antigen use across</cell></row><row><cell></cell><cell>countries, defining quality control standards, developing</cell></row><row><cell></cell><cell>reference reagents</cell></row><row><cell>Data Analytics</cell><cell>Standardizing and cleaning raw laboratory data, translating</cell></row><row><cell></cell><cell>cleaned data into useful epidemiologic inference by selecting</cell></row><row><cell></cell><cell>appropriate analytical approaches to answer questions of</cell></row><row><cell></cell><cell>interest, and developing user friendly analytical and</cell></row><row><cell></cell><cell>visualization pipelines</cell></row><row><cell>Sustainable</cell><cell>Demonstrating added value for initial engagement, generating</cell></row><row><cell>implementation</cell><cell>buy-in across national health systems, ensuring adequate</cell></row><row><cell></cell><cell>laboratory capacity and procurement, and interpreting data and</cell></row><row><cell></cell><cell>integrating results for decision making</cell></row><row><cell cols="2">Proposed Solutions Across Working Groups</cell></row><row><cell cols="2">Creation of an electronic platform to share resources and expertise</cell></row><row><cell cols="2">There is a strong need for information sharing platforms. New tools and resources</cell></row><row><cell cols="2">needed to support multiplex serosurveillance include a planning tool that would</cell></row></table><note><p><p>A unified platform could host these tools and other resources such as a central repository for antigens and standards, protocols, data packages and scripts, sample size calculation tools, best practices, training resources, and plain-language policy briefs and technical documents. Critically, this platform should also allow users to communicate with one another to troubleshoot problems and share experiences. Creating a single platform to address these needs could help develop and sustain a culture of collaboration while facilitating harmonization efforts where practical.</p>were identified as priorities for capacity building including the development of regional hubs and use of multiple training approaches such as on-site training, online traininganalyzing, and presenting data. Developing and validating positive and negative reference controls by antigen (e.g., through the United Kingdom's National Institute for Biological Standards and Control [NIBSC] or using validated recombinant antibodies) would lead to results that are more interpretable across assays, populations, and time-points. Developing a common panel with the most frequently used antigens across regions could also facilitate cross-country comparisons, though customization would still be needed to address country-specific priorities.</p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_4"><head></head><label></label><figDesc>To ensure the promotion of country ownership, initiatives are needed to build local capacity to couple beads, perform MBIAs, and analyze data that is coordinated with national governments and aligned with their priorities. More recently, efforts to transfer technology and build capacity in countries in the Americas<ref type="bibr" target="#b21">22,</ref><ref type="bibr" target="#b27">28</ref> and Africa<ref type="bibr" target="#b22">23</ref> have paved the way for future endeavors to scale-up multiplex serosurveillance. To move towards routine serosurveillance globally, additional funding is needed to fill research gaps and advance implementation in additional settings, including bolstering capacity in laboratories that do not yet have the technologies used in multi-pathogen serosurveillance.</figDesc><table /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_5"><head></head><label></label><figDesc>findings and conclusions in this report are those of the author(s) and do not necessarily represent the official position of the Centers for Disease Control and Prevention. The authors alone are responsible for the views expressed in this publication, and they do not necessarily represent the decisions or policies of the</figDesc><table><row><cell></cell><cell></cell><cell>USA</cell><cell></cell></row><row><cell>Andrew S.</cell><cell>PhD</cell><cell>Department of</cell><cell>azman@jhu.edu</cell></row><row><cell>Azman</cell><cell></cell><cell>Epidemiology, Johns</cell><cell></cell></row><row><cell></cell><cell></cell><cell>Hopkins Bloomberg</cell><cell></cell></row><row><cell></cell><cell></cell><cell>School of Public</cell><cell></cell></row><row><cell></cell><cell></cell><cell>Health, Baltimore, MD,</cell><cell></cell></row><row><cell></cell><cell></cell><cell>USA; Geneva</cell><cell></cell></row><row><cell></cell><cell></cell><cell>University Hospitals,</cell><cell></cell></row><row><cell></cell><cell></cell><cell>Geneva, Switzerland</cell><cell></cell></row><row><cell>Fiona R.</cell><cell>PhD</cell><cell>Center for Infectious</cell><cell>fiona.van.der.klis@rivm.nl</cell></row><row><cell>M. van der Klis</cell><cell></cell><cell>Disease Control National Institute for</cell><cell></cell></row><row><cell></cell><cell></cell><cell>Public Health and the</cell><cell></cell></row><row><cell></cell><cell></cell><cell>Environment (RIVM)</cell><cell></cell></row><row><cell></cell><cell></cell><cell>Bilthoven, The</cell><cell></cell></row><row><cell></cell><cell></cell><cell>Netherlands</cell><cell></cell></row><row><cell>Gerco den</cell><cell>PhD</cell><cell>Center for Infectious</cell><cell>gerco.den.hartog@rivm.nl</cell></row><row><cell>Hartog</cell><cell></cell><cell>Disease Control</cell><cell></cell></row><row><cell></cell><cell></cell><cell>National Institute for</cell><cell></cell></row><row><cell></cell><cell></cell><cell>Public Health and the</cell><cell></cell></row><row><cell></cell><cell></cell><cell>Environment (RIVM)</cell><cell></cell></row><row><cell></cell><cell></cell><cell>Bilthoven, The</cell><cell></cell></row><row><cell></cell><cell></cell><cell>Netherlands;</cell><cell></cell></row><row><cell></cell><cell></cell><cell>Laboratory of Medical</cell><cell></cell></row><row><cell cols="3">Immunology, Radboud Pan American Health Organization. UMC, Nijmegen, The</cell><cell></cell></row><row><cell></cell><cell></cell><cell>Netherlands</cell><cell></cell></row><row><cell>Christoph</cell><cell>PhD</cell><cell>London School of</cell><cell>Chris.Drakeley@lshtm.ac.uk</cell></row><row><cell>er Drakeley</cell><cell></cell><cell>Hygiene and Tropical Medicine, London UK</cell><cell></cell></row><row><cell>Christoph</cell><cell>PhD</cell><cell>Environmental Health</cell><cell>cheaney1@jhu.edu</cell></row><row><cell>er Heaney</cell><cell></cell><cell>and Engineering</cell><cell></cell></row><row><cell></cell><cell></cell><cell>Department, Johns</cell><cell></cell></row><row><cell></cell><cell></cell><cell>Hopkins Bloomberg</cell><cell></cell></row><row><cell></cell><cell></cell><cell>School of Public</cell><cell></cell></row><row><cell></cell><cell></cell><cell>Health, Baltimore, MD,</cell><cell></cell></row><row><cell></cell><cell></cell><cell>USA</cell><cell></cell></row><row><cell>Amy K</cell><cell>PhD</cell><cell>University of Georgia,</cell><cell>awinter@uga.edu</cell></row><row><cell>Winter</cell><cell></cell><cell>Athens, GA, USA</cell><cell></cell></row><row><cell>Henrik</cell><cell>PhD</cell><cell>Department of</cell><cell>hs743@cam.ac.uk</cell></row><row><cell>Salje</cell><cell></cell><cell>Genetics, University of</cell><cell></cell></row><row><cell></cell><cell></cell><cell>Cambridge,</cell><cell></cell></row><row><cell></cell><cell></cell><cell>Cambridge, UK</cell><cell></cell></row><row><cell>Isabel</cell><cell>PhD</cell><cell>Department of</cell><cell>Isabel.Rodriguez@ucsf.edu</cell></row></table></figure>
		</body>
		<back>

			<div type="acknowledgement">
<div><head>Acknowledgements</head><p>We would like to thank <rs type="person">Erica Carcelen</rs> and <rs type="person">NaQuasha Leonard</rs> from the <rs type="affiliation">International Vaccine Access Center at the Johns Hopkins Bloomberg School of Public Health</rs> for their logistic and operational support of the meeting. Additionally, we would like to acknowledge the notetakers from the <rs type="funder">Johns Hopkins Bloomberg School of Public Health</rs> (<rs type="person">Dr. Lindsay Avolio</rs> and <rs type="person">Dr. Sophie Bérubé</rs>) and the <rs type="funder">University of Colorado</rs> (<rs type="person">Shahjahan Ali</rs>, <rs type="person">Mattie Cassaday</rs>, and <rs type="person">Julia Poje</rs>). This meeting would not have been possible without the funding and guidance of the <rs type="funder">Bill and Melinda Gates Foundation</rs>. Finally, we are grateful to all the working group members of the <rs type="institution">Serosurveillance Summit</rs> for attending the meeting and contributing to the rich discussions.</p></div>
<div><head>Role of the funding source</head><p>The funding source provided guidance in the conceptualization of the meeting.</p></div>
<div><head>Saboyá-Díaz</head><p>Diseases Prevention, Control, and <rs type="funder">Elimination, Pan American Health Organization</rs>, <rs type="person">Washington DC</rs>, <rs type="institution">USA Diana L. Martin PhD Division of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, Atlanta</rs>, GA, USA hzx3@cdc.gov <rs type="person">William J. Moss MD Department</rs> of <rs type="affiliation">International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA</rs> wmoss1@jhu.edu</p></div>
			</div>
			<listOrg type="funding">
			</listOrg>
			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0" />			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<monogr>
		<title level="m" type="main">Defining collaborative surveillance: a core concept for strengthening the global architecture for health emergency preparedness, response, and resilience (HEPR)</title>
		<imprint>
			<date type="published" when="2023">2023</date>
			<publisher>World Health Organization</publisher>
		</imprint>
	</monogr>
	<note>World Health Organization</note>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Defining collaborative surveillance to improve decision making for public health emergencies and beyond</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">N</forename><surname>Archer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Abdelmalik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Cognat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">E</forename><surname>Grand</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Mott</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">I</forename><surname>Pavlin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Barakat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">F</forename><surname>Dowell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Elmahal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Golding</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Gongal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Hamblion</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Hersey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kato</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">L</forename><surname>Koua</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">The Lancet</title>
		<imprint>
			<biblScope unit="volume">401</biblScope>
			<biblScope unit="page" from="1831" to="1834" />
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Integrated Serologic Surveillance of Population Immunity and Disease Transmission</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">F</forename><surname>Arnold</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">M</forename><surname>Scobie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Priest</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Lammie</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Emerg Infect Dis</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="1188" to="1194" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">SeroTracker: a global SARS-CoV-2 seroprevalence dashboard</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">K</forename><surname>Arora</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Joseph</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">V</forename><surname>Wyk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Rocco</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Atmaja</surname></persName>
		</author>
		<author>
			<persName><forename type="first">May</forename><forename type="middle">E</forename><surname>Yan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Bobrovitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Chevrier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Cheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Williamson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Buckeridge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Infect Dis</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="75" to="e76" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Multiplex bead array assays: performance evaluation and comparison of sensitivity to ELISA</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">F</forename><surname>Elshal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Mccoy</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Methods San Diego Calif</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="page" from="317" to="323" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">A Diagnostics Platform for the Integrated Mapping, Monitoring, and Surveillance of Neglected Tropical Diseases: Rationale and Target Product Profiles</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">W</forename><surname>Solomon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Engels</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Bailey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">M</forename><surname>Blake</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Brooker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J-X</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J-H</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">S</forename><surname>Churcher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Drakeley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Edwards</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Fenwick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>French</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">F</forename><surname>Gabrielli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">C</forename><surname>Grassly</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Harding-Esch</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS Negl Trop Dis</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page">1746</biblScope>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Detection of IgG-class antibodies to measles, mumps, rubella, and varicellazoster virus using a multiplex bead immunoassay</title>
		<author>
			<persName><forename type="first">N</forename><surname>Dhiman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Jespersen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">O</forename><surname>Rollins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Harring</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Beito</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Binnicker</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Diagn Microbiol Infect Dis</title>
		<imprint>
			<biblScope unit="volume">67</biblScope>
			<biblScope unit="page" from="346" to="349" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Measles and rubella serosurvey identifies rubella immunity gap in young adults of childbearing age in Zambia: The added value of nesting a serological survey within a post-campaign coverage evaluation survey</title>
		<author>
			<persName><forename type="first">K</forename><surname>Hayford</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Mutembo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Carcelen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">K</forename><surname>Matakala</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Munachoonga</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Winter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Wanyiri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Searle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">D</forename><surname>Mwansa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Mwiche</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Phiri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Book</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">E</forename><surname>Thuma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Moss</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Vaccine</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page" from="2387" to="2393" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Simultaneous Detection of Haemophilus influenzae Type b Polysaccharide-Specific Antibodies and Neisseria meningitidis Serogroup A, C, Y, and W-135 Polysaccharide-Specific Antibodies in a Fluorescent-Bead-Based Multiplex Immunoassay</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>De Voer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Schepp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Fga</forename><surname>Versteegh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Frm</forename><surname>Van Der Klis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Gam</forename><surname>Berbers</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Vaccine Immunol CVI</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="433" to="436" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Development of a respiratory virus panel test for detection of twenty human respiratory viruses by use of multiplex PCR and a fluid microbead-based assay</title>
		<author>
			<persName><forename type="first">J</forename><surname>Mahony</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Chong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Merante</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Yaghoubian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Sinha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Lisle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Janeczko</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Microbiol</title>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="page" from="2965" to="2970" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Community-level chlamydial serology for assessing trachoma elimination in trachoma-endemic Niger</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Oldenburg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Cooley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Amza</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Kadri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Nassirou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">Y</forename><surname>Cotter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">E</forename><surname>Stoller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">K</forename><surname>West</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Bailey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Keenan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">D</forename><surname>Gaynor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">C</forename><surname>Porco</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">M</forename><surname>Lietman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Martin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS Negl Trop Dis</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page">7127</biblScope>
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Serology for trachoma surveillance after cessation of mass drug administration</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Martin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Bid</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Sandi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">B</forename><surname>Goodhew</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Massae</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Lasway</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Philippin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Makupa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Molina</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Holland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Dcw</forename><surname>Mabey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Drakeley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Lammie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">W</forename><surname>Solomon</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS Negl Trop Dis</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page">3555</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Longitudinal analysis of antibody responses to trachoma antigens before and after mass drug administration</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">B</forename><surname>Goodhew</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Smg</forename><surname>Morgan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Switzer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Munoz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Dize</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Gaydos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Mkocha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">K</forename><surname>West</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E</forename><surname>Wiegand</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Lammie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Martin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMC Infect Dis</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page">216</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Integration of Multiplex Bead Assays for Parasitic Diseases into a National, Population-Based Serosurvey of Women 15-39 Years of Age in Cambodia</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Priest</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Jenks</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Moss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Mao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Buth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Wannemuehler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Soeung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">W</forename><surname>Lucchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Udhayakumar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Gregory</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Huy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Muth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Lammie</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS Negl Trop Dis</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page">4699</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Investigation of Chagas disease in four periurban areas in northeastern Brazil: epidemiologic survey in man, vectors, non-human hosts and reservoirs</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Lima</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Sarquis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">G</forename><surname>De Oliveira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">F</forename><surname>Gomes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Coutinho</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">F</forename><surname>Daflon-Teixeira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">K</forename><surname>Toma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Britto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">R</forename><surname>Teixeira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D'</forename><surname>Andrea</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">S</forename><surname>Jansen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Bóia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">N</forename><surname>Carvalho-Costa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">A</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Trans R Soc Trop Med Hyg</title>
		<imprint>
			<biblScope unit="volume">106</biblScope>
			<biblScope unit="page" from="143" to="149" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">High-throughput malaria serosurveillance using a one-step multiplex bead assay</title>
		<author>
			<persName><forename type="first">E</forename><surname>Rogier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Van Den Hoogen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Herman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Gurrala</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Joseph</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Stresman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Presume</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Romilus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Mondelus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Elisme</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Ashton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Chang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Lemoine</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Druetz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">P</forename><surname>Eisele</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Malar J</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page">402</biblScope>
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Evaluation of Immunoglobulin G Responses to Plasmodium falciparum and Plasmodium vivax in Malian School Children Using Multiplex Bead Assay</title>
		<author>
			<persName><forename type="first">E</forename><surname>Rogier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Moss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">N</forename><surname>Chard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Trinies</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Doumbia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Freeman</forename><surname>Mc</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Lammie</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Trop Med Hyg</title>
		<imprint>
			<biblScope unit="volume">96</biblScope>
			<biblScope unit="page" from="312" to="318" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Development of a Bead-Based Multiplex Assay for Use in Multianalyte Screening and Surveillance of HIV, Viral Hepatitis, Syphilis, and Herpes</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">L</forename><surname>Yufenyuy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Vedapuri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Zheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Cooley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Danavall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Mayur</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kodani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Tun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">F</forename><surname>Fakile</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Martin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kamili</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Karem</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">S</forename><surname>Parekh</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Microbiol</title>
		<imprint>
			<biblScope unit="volume">60</biblScope>
			<biblScope unit="page">234821</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<author>
			<persName><forename type="first">E</forename><surname>Rogier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Plucinski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Candrinho</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Moss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Gibbons</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Colborn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Higgins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Chambe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Muchanga</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Muguande</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Matsinhe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Mathe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Doyle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Zulliger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Saifodine</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Adaptation to a Multiplex Bead Assay and Seroprevalence to Rift Valley Fever N Protein: Nampula Province</title>
		<meeting><address><addrLine>Mozambique</addrLine></address></meeting>
		<imprint>
			<date type="published" when="2022">2022</date>
			<biblScope unit="volume">96</biblScope>
			<biblScope unit="page">67222</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Spatial Distribution and Burden of Emerging Arboviruses in French Guiana</title>
		<author>
			<persName><forename type="first">S</forename><surname>Bailly</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Rousset</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Fritzell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Hozé</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ben</forename><surname>Achour</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Berthelot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Enfissi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Vanhomwegen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Salje</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Fernandes-Pellerin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Saout</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Lavergne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Manuguerra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J-C</forename><surname>Carod</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J-F</forename><surname>Djossou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Viruses</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page">1299</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Performance of SARS-CoV-2 Antigens in a Multiplex Bead Assay for Integrated Serological Surveillance of Neglected Tropical and Other Diseases</title>
		<author>
			<persName><forename type="first">S</forename><surname>Gwyn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Abubakar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Akinmulero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Bergeron</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><forename type="middle">N</forename><surname>Blessing</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Chaitram</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Coughlin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">B</forename><surname>Dawurung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">N</forename><surname>Dickson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Esiekpe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Evbuomwan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Greby</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">C</forename><surname>Iriemenam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Kainulainen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">A</forename><surname>Naanpoen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Trop Med Hyg</title>
		<imprint>
			<biblScope unit="volume">107</biblScope>
			<biblScope unit="page" from="260" to="267" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Lessons learned from the implementation of integrated serosurveillance of communicable diseases in the Americas</title>
		<author>
			<persName><forename type="first">M-I</forename><surname>Saboyá-Díaz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">G</forename><surname>Castellanos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Morice</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Ade</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Rey-Benito</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">M</forename><surname>Cooley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">M</forename><surname>Scobie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E</forename><surname>Wiegand</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Coughlin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Martin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Rev Panam Salud Pública</title>
		<imprint>
			<biblScope unit="volume">47</biblScope>
			<biblScope unit="page">53</biblScope>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Integrated Cross-Sectional Multiplex Serosurveillance of IgG Antibody Responses to Parasitic Diseases and Vaccines in Coastal Kenya</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Njenga</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">M</forename><surname>Kanyi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">F</forename><surname>Arnold</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Matendechero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">K</forename><surname>Onsongo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">Y</forename><surname>Won</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Priest</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Trop Med Hyg</title>
		<imprint>
			<biblScope unit="volume">102</biblScope>
			<biblScope unit="page" from="164" to="176" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Effect of biannual azithromycin distribution on antibody responses to malaria, bacterial, and protozoan pathogens in Niger</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Arzika</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Maliki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">B</forename><surname>Goodhew</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Rogier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Priest</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Lebas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O'</forename><surname>Brien</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">S</forename><surname>Le</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Oldenburg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Doan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Porco</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">C</forename><surname>Keenan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Lietman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">M</forename><surname>Martin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Arnold</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">F</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Commun</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page">976</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Vaccination coverage survey and seroprevalence among forcibly displaced Rohingya children</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">R</forename><surname>Feldstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Bennett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">F</forename><surname>Estivariz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">M</forename><surname>Cooley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Weil</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Billah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Uzzaman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Bohara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Vandenent</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Adhikari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Leidman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hasan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Akhtar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Hasman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Conklin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS Med</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page">1003071</biblScope>
			<date type="published" when="2018">2020. 2018</date>
			<pubPlace>Cox&apos;s Bazar, Bangladesh</pubPlace>
		</imprint>
	</monogr>
	<note>A cross-sectional study</note>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">No Serological Evidence of Trachoma or Yaws Among Residents of Registered Camps and Makeshift Settlements in Cox&apos;s Bazar, Bangladesh</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">M</forename><surname>Cooley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">R</forename><surname>Feldstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Bennett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">F</forename><surname>Estivariz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Weil</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Bohara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Vandenent</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Mainul</forename><surname>Hasan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Akhtar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Uzzaman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Billah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Conklin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Ehlman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">C</forename><surname>Asiedu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Solomon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">W</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Trop Med Hyg</title>
		<imprint>
			<biblScope unit="volume">104</biblScope>
			<biblScope unit="page" from="2031" to="2037" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Multiplex Bead Assay for Integrated Serological Surveillance of Communicable Diseases in the Region of the Americas</title>
	</analytic>
	<monogr>
		<title level="m">Report of the third regional meeting</title>
		<imprint>
			<publisher>Pan American Health Organization</publisher>
			<date type="published" when="2020-03-05">2020. Cuernavaca, 4-5 March 2020</date>
		</imprint>
		<respStmt>
			<orgName>WHO | Pan American Health Organization</orgName>
		</respStmt>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<monogr>
		<title level="m" type="main">Toolkit for Integrated Serosurveillance of Communicable Diseases in the Americas -PAHO/WHO | Pan American Health Organization</title>
		<author>
			<persName><surname>Anon</surname></persName>
		</author>
		<ptr target="https://www.paho.org/en/documents/toolkit-integrated-serosurveillance-communicable-diseases-americas" />
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Building an integrated serosurveillance platform to inform public health interventions: Insights from an experts&apos; meeting on serum biomarkers</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">E</forename><surname>Wiens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Jauregui</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">F</forename><surname>Arnold</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Banke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Wade</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Hayford</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ac-S</forename><surname>Denis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">H</forename><surname>Hall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Salje</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Rodriguez-Barraquer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Azman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Vernet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">T</forename><surname>Leung</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Surveillance on behalf of the C on IB</title>
		<imprint>
			<date type="published" when="2022">2022</date>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page">10657</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<monogr>
		<title level="m" type="main">Nationally-representative serostudy of dengue in Bangladesh allows generalizable disease burden estimates</title>
		<author>
			<persName><forename type="first">H</forename><surname>Salje</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">K</forename><surname>Paul</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Paul</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Rodriguez-Barraquer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Rahman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Alam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Rahman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">M</forename><surname>Al-Amin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Heffelfinger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Gurley</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2019">2019</date>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page">42869</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Nationally representative SARS-CoV-2 antibody prevalence estimates after the first epidemic wave in Mexico</title>
		<author>
			<persName><forename type="first">A</forename><surname>Basto-Abreu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Carnalla</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Torres-Ibarra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Romero-Martínez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Martínez-Barnetche</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>López-Martínez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Aparicio-Antonio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Shamah-Levy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Alpuche-Aranda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Rivera</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Barrientos-Gutierrez</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Commun</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page">589</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Evaluating the effect of measles and rubella mass vaccination campaigns on seroprevalence in India: a before-and-after cross-sectional household serosurvey in four districts</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">V</forename><surname>Murhekar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Gupta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">Z</forename><surname>Hasan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Kumar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">S</forename><surname>Kumar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Prosperi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">N</forename><surname>Sapkal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jwv</forename><surname>Thangaraj</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Kaduskar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Bhatt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">R</forename><surname>Deshpande</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><forename type="middle">P</forename><surname>Thankappan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">K</forename><surname>Bansal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Chauhan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">S</forename><surname>Grover</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Glob Health</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="1655" to="e1664" />
			<date type="published" when="2018">2022. 2018-2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Multiplex serology for impact evaluation of bed net distribution on burden of lymphatic filariasis and four species of human malaria in northern Mozambique</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Plucinski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Candrinho</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Chambe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Muchanga</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Muguande</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Matsinhe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Mathe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Rogier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Doyle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Zulliger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Colborn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Saifodine</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Lammie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Priest</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS Negl Trop Dis</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page">6278</biblScope>
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Serosurveillance to Monitor Onchocerciasis Elimination: The Ugandan Experience</title>
		<author>
			<persName><forename type="first">D</forename><surname>Oguttu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Byamukama</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">R</forename><surname>Katholi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Habomugisha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Nahabwe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ngabirano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">K</forename><surname>Hassan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Lakwo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Katabarwa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">O</forename><surname>Richards</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">R</forename><surname>Unnasch</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Trop Med Hyg</title>
		<imprint>
			<biblScope unit="volume">90</biblScope>
			<biblScope unit="page" from="339" to="345" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<monogr>
		<author>
			<persName><forename type="first">Andrea</forename><surname>Carcelen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Alex</forename><surname>Kong</surname></persName>
		</author>
		<author>
			<persName><surname>Hegde</surname></persName>
		</author>
		<author>
			<persName><surname>Sonia</surname></persName>
		</author>
		<author>
			<persName><surname>Takahashi</surname></persName>
		</author>
		<author>
			<persName><surname>Saki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">William</forename><surname>Moss</surname></persName>
		</author>
		<title level="m">Serosurveillance Summit Meeting Report</title>
		<meeting><address><addrLine>Baltimore, Maryland, USA</addrLine></address></meeting>
		<imprint>
			<publisher>Johns Hopkins Bloomberg School of Public Health International Vaccine Access Center</publisher>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Projected costs associated with school-based screening to inform deployment of Dengvaxia: Vietnam as a case study</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">C</forename><surname>Turner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Wills</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Rahman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Quoc</forename><surname>Cuong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Thwaites</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">E</forename><surname>Boni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">F</forename><surname>Clapham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">E</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Trans R Soc Trop Med Hyg</title>
		<imprint>
			<biblScope unit="volume">112</biblScope>
			<biblScope unit="page" from="369" to="377" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Timeliness of reporting of SARS-CoV-2 seroprevalence results and their utility for infectious disease surveillance</title>
		<author>
			<persName><forename type="first">C</forename><surname>Donnici</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Ilincic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Cao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Deveaux</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Clifton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Buckeridge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Bobrovitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">K</forename><surname>Arora</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Epidemics</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="page">100645</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">How do we…form and coordinate a national serosurvey of SARS-CoV-2 within the blood collection industry?</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">V</forename><surname>Fink</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Fisher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Sulaeman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Dave</forename><forename type="middle">H</forename><surname>Levy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Mccann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Di</forename><surname>Germanio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Notari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">V</forename><surname>Ep</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Green</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Cyrus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Williamson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Saa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Haynes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Groves</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Mathew</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Transfusion</title>
		<imprint>
			<biblScope unit="volume">62</biblScope>
			<biblScope unit="page" from="1321" to="1333" />
			<date type="published" when="2022">2022</date>
			<pubPlace>Paris</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Development of a new platform for neglected tropical disease surveillance</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Lammie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Moss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Brook</forename><surname>Goodhew</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Hamlin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Krolewiecki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>West</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">K</forename><surname>Priest</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Parasitol</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="page" from="797" to="800" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">V</forename><surname>Murhekar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Kumar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Kamaraj</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Khan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">R</forename><surname>Allam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Barde</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Dwibedi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kanungo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Mohan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Mohanty</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Roy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Sagar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Savargaonkar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">V</forename><surname>Tandale</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">K</forename><surname>Topno</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Hepatitis-B virus infection in India: Findings from a nationally representative serosurvey</title>
		<imprint>
			<date type="published" when="2020">2020</date>
			<biblScope unit="volume">100</biblScope>
			<biblScope unit="page" from="455" to="460" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">WHO International Standard for evaluation of the antibody response to COVID-19 vaccines: call for urgent action by the scientific community</title>
		<author>
			<persName><forename type="first">I</forename><surname>Knezevic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Mattiuzzo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Page</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Minor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Griffiths</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Nuebling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Moorthy</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Microbe</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page" from="235" to="e240" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Immune surveillance for vaccine-preventable diseases</title>
		<author>
			<persName><forename type="first">G</forename><surname>Den Hartog</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Van Binnendijk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A-M</forename><surname>Buisman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Gam</forename><surname>Berbers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Frm</forename><surname>Van Der Klis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Expert Rev Vaccines</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="327" to="339" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Comparison of antibody response between boys and girls after infant and childhood vaccinations in the Netherlands</title>
		<author>
			<persName><forename type="first">J</forename><surname>Hoes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Knol</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Mollema</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Buisman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">E</forename><surname>De Melker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Frm</forename><surname>Van Der Klis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Vaccine</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page" from="4504" to="4510" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Waning of antibody levels induced by a 13valent pneumococcal conjugate vaccine, using a 3 + 0 schedule, within the first year of life among children younger than 5 years in Blantyre, Malawi: an observational, population-level, serosurveillance study</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">D</forename><surname>Swarthout</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Myr</forename><surname>Henrion</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Thindwa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Meiring</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Mbewe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kalizang'oma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Brown</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Msefula</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Moyo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Mataya</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Barnaba</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Pearce</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Gordon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Goldblatt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>French</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Infect Dis</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="1737" to="1747" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">Tetanus Immunity Gaps in Children 5-14 Years and Men ≥ 15 Years of Age Revealed by Integrated Disease Serosurveillance in Kenya, Tanzania, and Mozambique</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">M</forename><surname>Scobie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Patel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Martin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Mkocha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Njenga</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Odiere</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Pelletreau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Priest</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Thompson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">Y</forename><surname>Won</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Lammie</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Trop Med Hyg</title>
		<imprint>
			<biblScope unit="volume">96</biblScope>
			<biblScope unit="page" from="415" to="420" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">Fine-scale heterogeneity in Schistosoma mansoni force of infection measured through antibody response</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">F</forename><surname>Arnold</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Kanyi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Njenga</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">O</forename><surname>Rawago</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Priest</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">E</forename><surname>Secor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Lammie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">Y</forename><surname>Won</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Odiere</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc Natl Acad Sci U S A</title>
		<imprint>
			<biblScope unit="volume">117</biblScope>
			<biblScope unit="page" from="23174" to="23181" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">Comparison of one single-antigen assay and three multi-antigen SARS-CoV-2 IgG assays in Nigeria</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">C</forename><surname>Iriemenam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">A</forename><surname>Ige</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Greby</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><forename type="middle">O</forename><surname>Okunoye</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Uwandu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Aniedobe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">O</forename><surname>Nwaiwu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Mba</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Okoli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">E</forename><surname>William</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ehoche</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Mpamugo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Mitchell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Stafford</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">N</forename><surname>Thomas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Virol Plus</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page">100139</biblScope>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">Cross-Reactivity of Two SARS-CoV-2 Serological Assays in a Setting Where Malaria Is Endemic</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">C</forename><surname>Steinhardt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Ige</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">C</forename><surname>Iriemenam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Greby</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Hamada</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Uwandu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Aniedobe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Stafford</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Abimiku</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Mba</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Agala</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Okunoye</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Mpamugo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Swaminathan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Onokevbagbe</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Microbiol</title>
		<imprint>
			<biblScope unit="volume">59</biblScope>
			<biblScope unit="page" from="514" to="521" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">Non-falciparum malaria infection and IgG seroprevalence among children under 15 years in Nigeria</title>
		<author>
			<persName><forename type="first">C</forename><surname>Herman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Leonard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Uhomoibhi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Maire</forename><forename type="middle">M</forename><surname>Moss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Inyang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Abubakar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ogunniyi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Mba</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Greby</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Okoye</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">I</forename><surname>Iriemenam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">C</forename><surname>Maikore</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Steinhardt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Rogier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Commun</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page">1360</biblScope>
			<date type="published" when="2018">2023. 2018</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
